Research Article
The Relationship between MACC1/c-Met/Cyclin D1 Axis Expression and Prognosis in ESCC
Table 2
The expression of MACC1 and its relationship with clinicopathological parameters in Han and Kazakh patients of ESCC.
| | Clinical characteristics (Han vs. Kazakh) | Han | value | Kazakh | value | | Positive () | Negative () | Positive () | Negative (n = 55) |
| | Age | | | | | | | | <60 (31.0% vs. 45.6%) | 11 (19.0%) | 7 (12.1%) | | 32 (28.1%) | 20 (17.5%) | | | ≥60 (69.0% vs. 54.4%) | 22 (37.9%) | 18 (31.0%) | 0.67 | 27 (23.7%) | 35 (30.7%) | 0.06 | | Gender | | | | | | | | Male (74.1% vs. 65.8%) | 24 (41.4%) | 19 (32.8%) | | 37 (32.5%) | 38 (33.3%) | | | Female (25.9% vs. 34.2%) | 9 (15.5%) | 6 (10.3%) | 0.78 | 22 (19.3%) | 17 (14.9%) | 0.47 | | Tumor location | | | | | | | | Upper (6.9% vs. 1.8%) | 3 (5.2%) | 1 (1.7%) | | 1 (0.9%) | 1 (0.9%) | | | Middle (48.3% vs. 59.6%) | 15 (25.9%) | 13 (22.4%) | | 33 (28.9%) | 35 (30.7%) | | | Lower (44.8% vs. 38.6%) | 15 (25.9%) | 11 (19.0%) | 0.71 | 25 (21.9%) | 19 (16.7%) | 0.69 | | Tumor size | | | | | | | | <3 cm (29.3% vs. 29.8%) | 6 (10.3%) | 11 (19.0%) | | 14 (12.3%) | 20 (17.5%) | | | ≥3 cm (70.7% vs. 70.2%) | 27 (46.6%) | 14 (24.1%) | 0.03 | 45 (39.5%) | 35 (30.7%) | 0.14 | | Degree of differentiation | | | | | | | | Poor (34.5% vs. 18.4%) | 12 (20.7%) | 8 (13.8%) | | 13 (11.4%) | 8 (7.0%) | | | Moderate (53.4% vs. 51.8%) | 16 (27.6%) | 15 (25.9%) | | 25 (21.9%) | 34 (29.8%) | | | Well (12.1% vs. 29.8%) | 5 (8.6%) | 2 (3.4%) | 0.60 | 21 (18.4%) | 13 (11.4%) | 0.12 | | Lymph node metastasis | | | | | | | | Negative (63.8% vs. 73.7%) | 22 (37.9%) | 15 (25.9%) | | 44 (38.6%) | 40 (35.1%) | | | Positive (36.2% vs. 26.3%) | 11 (19.0%) | 10 (17.2%) | 0.60 | 15 (13.2%) | 15 (13.2%) | 0.82 | | Invasive depth | | | | | | | | Mucosa (6.9% vs. 0.9%) | 2 (3.4%) | 2 (3.4%) | | 1 (0.9%) | 0 (0.0%) | | | Muscularis (48.3% vs. 43.9%) | 11 (19.0%) | 17 (29.3%) | | 27 (23.7%) | 23 (20.2%) | | | Full thickness (44.8% vs. 55.3%) | 20 (34.5%) | 6 (10.3%) | 0.02 | 31 (27.2%) | 32 (28.1%) | 0.45 | | AJCC stage | | | | | | | | IA+B (6.9% vs. 7.9%) | 3 (5.2%) | 1 (1.7%) | | 8 (7.0%) | 1 (0.9%) | | | IIA+B (33.3% vs. 65.8%) | 20 (34.5%) | 18 (31.0%) | | 36 (31.6%) | 39 (34.2%) | | | IIIA+B (20.7% vs. 17.5%) | 7 (12.1%) | 5 (8.6%) | | 11 (9.6%) | 9 (7.9%) | | | IVA+B (6.9% vs. 5.8%) | 3 (5.2%) | 1 (1.7%) | 0.70 | 4 (3.5%) | 6 (5.3%) | 0.11 | | Vascular invasion | | | | | | | | Negative (82.8% vs. 81.6%) | 27 (46.6%) | 21 (36.2%) | | 49 (43.0%) | 44 (38.6%) | | | Positive (17.2% vs. 18.4%) | 6 (10.3%) | 4 (6.9%) | 0.83 | 10 (8.8%) | 11 (9.6%) | 0.68 | | Nerve invasion | | | | | | | | Negative (82.8% vs. 76.3%) | 27 (46.6%) | 21 (36.2%) | | 50 (43.9%) | 37 (32.5%) | | | Positive (17.2% vs. 23.7%) | 6 (10.3%) | 4 (6.9%) | 0.83 | 9 (7.9%) | 18 (15.8%) | 0.03 | | Hematogenous metastasis | | | | | | | | Negative (81.0% vs. 86.8%) | 27 (46.6%) | 20 (34.5%) | | 50 (43.9%) | 49 (43.0%) | | | Positive (19.0% vs. 13.2%) | 6 (10.3%) | 5 (8.6%) | 0.87 | 9 (7.9%) | 6 (5.3%) | 0.49 |
|
|
Abbreviations: ESCC: esophageal squamous cell carcinoma; AJCC: American Joint Committee on Cancer.
|
